Lincoln Pharmaceuticals FY26 Financial Performance

Consolidated Revenue: ₹671.03 Crore | Net Profit: ₹87.89 Crore

Reader Takeaway: Record revenue growth driven by global exports, though expansion into regulated markets remains a key long-term monitorable.

What just happened

Lincoln Pharmaceuticals has closed the fiscal year ending March 31, 2026, with its highest-ever financial performance. Consolidated revenue from operations rose to ₹671.03 crore from ₹623.23 crore in the previous year. Total income reached ₹704.48 crore. The company reported a net profit after tax of ₹87.89 crore, reflecting a steady improvement from ₹82.35 crore in FY25. The Board of Directors has recommended a final dividend of ₹1.80 per equity share for the fiscal year.

Why this matters

The company’s ability to remain net debt-free while financing growth through internal accruals provides significant balance sheet strength. With international markets now contributing 58.5% of total revenue, the shift toward regulated markets like Canada, supported by EU-GMP and TGA certifications, marks a pivotal move to improve profit margins and reduce dependence on domestic pricing pressure.

Strategic Growth Roadmap

Lincoln Pharmaceuticals has set an ambitious target to reach ₹1,000 crore in revenue within three years. The strategy centers on:

• Therapeutic expansion into chronic and lifestyle-related segments like cardiac and diabetic care.
• Improving supply-chain resilience through the Mehsana Cephalosporin facility and a new bulk drug plant.
• Aggressive global expansion aiming for presence in 90+ countries.
• Leveraging an R&D pipeline of approximately 700 products.

What to track next

Investors should monitor the integration of the Canadian market and progress on the upcoming bulk drug manufacturing plant. The 32nd Annual General Meeting is scheduled for September 30, 2026, with a dividend record date of September 11, 2026.